Mechanisms of drug resistance in kinases

Bibliography

• Johnson LN. Protein kinase inhibitors: contributions from structure to clinical compounds. Q Rev Biophys 2009;42(1):1-40
   PubMed Web of Science ®Google Scholar
• Greenman C, Stephens P, Smith R, Patterns of somatic mutation in human cancer genomes. Nature 2007;446(7132):153-8
   PubMed Web of Science ®Google Scholar
• Lahiry P, Torkamani A, Schork NJ, Hegele RA. Kinase mutations in human disease: interpreting genotype-phenotype relationships. Nat Rev Genet 2010;11(1):60-74
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Kantarjian H, Cortes J. Imatinib and beyond – exploring the full potential of targeted therapy for CML. Nat Rev Clin Oncol 2009;6(9):535-43
   PubMed Web of Science ®Google Scholar
• Trowe T, Boukouvala S, Calkins K, EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation. Clin Cancer Res 2008;14(8):2465-75
   PubMed Web of Science ®Google Scholar
• Lim KH, Huang MJ, Chen LT, Molecular analysis of secondary kinase mutations in imatinib-resistant gastrointestinal stromal tumors. Med Oncol 2008;25(2):207-13
   PubMed Web of Science ®Google Scholar
• Puxeddu E, Romagnoli S, Dottorini ME. Targeted therapies for advanced thyroid cancer. Curr Opin Oncol 2011;23(1):13-21
   PubMed Web of Science ®Google Scholar
• Cuny GD. Kinase inhibitors as potential therapeutics for acute and chronic neurodegenerative conditions. Curr Pharm Des 2009;15(34):3919-39
   PubMed Web of Science ®Google Scholar
• Janne PA, Gray N, Settleman J. Factors underlying sensitivity of cancers to small-molecule kinase inhibitors. Nat Rev Drug Discov 2009;8(9):709-23
   PubMed Web of Science ®Google Scholar
• Rokosz LL, Beasley JR, Carroll CD, Kinase inhibitors as drugs for chronic inflammatory and immunological diseases: progress and challenges. Expert Opin Ther Targets 2008;12(7):883-903
   PubMed Web of Science ®Google Scholar
• Won J, Lee GH. T-cell-targeted signaling inhibitors. Int Rev Immunol 2008;27(1-2):19-41
   PubMed Web of Science ®Google Scholar
• Gaestel M, Kotlyarov A, Kracht M. Targeting innate immunity protein kinase signalling in inflammation. Nat Rev Drug Discov 2009;8(6):480-99
   PubMed Web of Science ®Google Scholar
• Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat Rev 2009;9(1):28-39
   Google Scholar
• Opar A. Kinase inhibitors attract attention as oral rheumatoid arthritis drugs. Nat Rev Drug Discov 2010;9(4):257-8
   PubMed Web of Science ®Google Scholar
• Ghoreschi K, Laurence A, O'Shea JJ. Selectivity and therapeutic inhibition of kinases: to be or not to be? Nat Immunol 2009;10(4):356-60
   PubMed Web of Science ®Google Scholar
• Bixby D, Talpaz M. Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance. Hematology Am Soc Hematol Educ Program 2009:461-76
   PubMedGoogle Scholar
• Valent P. Standard treatment of Ph+ CML in 2010: how, when and where not to use what BCR/ABL1 kinase inhibitor? Eur J Clin Invest 2010;40(10):918-31
   PubMed Web of Science ®Google Scholar
• Ihle NT, Powis G. Inhibitors of phosphatidylinositol-3-kinase in cancer therapy. Mol Aspects Med 2010;31(2):135-44
   PubMed Web of Science ®Google Scholar
• Druker BJ, Tamura S, Buchdunger E, Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2(5):561-6
   PubMed Web of Science ®Google Scholar
• NIH. Available from: http://clinicaltrials.gov. 2010
   Google Scholar
• Engelman JA, Settleman J. Acquired resistance to tyrosine kinase inhibitors during cancer therapy. Curr Opin Genet Dev 2008;18(1):73-9
   PubMed Web of Science ®Google Scholar
• Daub H, Specht K, Ullrich A. Strategies to overcome resistance to targeted protein kinase inhibitors. Nat Rev Drug Discov 2004;3(12):1001-10
   PubMed Web of Science ®Google Scholar
• Buschbeck M. Strategies to overcome resistance to targeted protein kinase inhibitors in the treatment of cancer. Drugs R D 2006;7(2):73-86
   PubMedGoogle Scholar
• La Rosee P, Hochhaus A. Molecular pathogenesis of tyrosine kinase resistance in chronic myeloid leukemia. Curr Opin Hematol 2010;17(2):91-6
   PubMed Web of Science ®Google Scholar
• Krishnamurty R, Maly DJ. Biochemical mechanisms of resistance to small-molecule protein kinase inhibitors. ACS Chem Biol 2010;5(1):121-38
   PubMed Web of Science ®Google Scholar
• Gorre ME, Mohammed M, Ellwood K, Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293(5531):876-80
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Kantarjian H, Cortes J. Flying under the radar: the new wave of BCR-ABL inhibitors. Nat Rev Drug Discov 2007;6(10):834-48
   PubMed Web of Science ®Google Scholar
• Marmorstein R. Anticipating drug resistance in the MAP kinase pathway. Pigment Cell Melanoma Res 2010;23(1):7-9
   PubMed Web of Science ®Google Scholar
• Girdler F, Sessa F, Patercoli S, Molecular basis of drug resistance in aurora kinases. Chem Biol 2008;15(6):552-62
   PubMed Web of Science ®Google Scholar
• Emery CM, Vijayendran KG, Zipser MC, MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA 2009;106(48):20411-16
   PubMed Web of Science ®Google Scholar
• Zunder ER, Knight ZA, Houseman BT, Discovery of drug-resistant and drug-sensitizing mutations in the oncogenic PI3K isoform p110 alpha. Cancer Cell 2008;14(2):180-92
   PubMed Web of Science ®Google Scholar
• Kitzen JJ, de Jonge MJ, Verweij J. Aurora kinase inhibitors. Crit Rev Oncol Hematol 2010;73(2):99-110
   PubMed Web of Science ®Google Scholar
• Warmuth M, Kim S, Gu XJ, Ba/F3 cells and their use in kinase drug discovery. Curr Opin Oncol 2007;19(1):55-60
   PubMed Web of Science ®Google Scholar
• Barouch-Bentov R, Che J, Lee CC, A conserved salt bridge in the G loop of multiple protein kinases is important for catalysis and for in vivo Lyn function. Mol Cell 2009;33(1):43-52
   PubMed Web of Science ®Google Scholar
• Liu Y, Gray NS. Rational design of inhibitors that bind to inactive kinase conformations. Nat Chem Biol 2006;2(7):358-64
   PubMed Web of Science ®Google Scholar
• Engen JR, Wales TE, Hochrein JM, Structure and dynamic regulation of Src-family kinases. Cell Mol Life Sci 2008;65(19):3058-73
   PubMed Web of Science ®Google Scholar
• Pawson T, Kofler M. Kinome signaling through regulated protein-protein interactions in normal and cancer cells. Curr Opin Cell Biol 2009;21(2):147-53
   PubMed Web of Science ®Google Scholar
• Shan Y, Seeliger MA, Eastwood MP, A conserved protonation-dependent switch controls drug binding in the Abl kinase. Proc Natl Acad Sci USA 2009;106(1):139-44
   PubMed Web of Science ®Google Scholar
• Nagar B, Hantschel O, Seeliger M, Organization of the SH3-SH2 unit in active and inactive forms of the c-Abl tyrosine kinase. Mol Cell 2006;21(6):787-98
   PubMed Web of Science ®Google Scholar
• Levinson NM, Kuchment O, Shen K, A Src-like inactive conformation in the abl tyrosine kinase domain. PLoS Biol 2006;4(5):e144
   PubMed Web of Science ®Google Scholar
• Nagar B, Hantschel O, Young MA, Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell 2003;112(6):859-71
   PubMed Web of Science ®Google Scholar
• Hantschel O, Nagar B, Guettler S, A myristoyl/phosphotyrosine switch regulates c-Abl. Cell 2003;112(6):845-57
   PubMed Web of Science ®Google Scholar
• Young MA, Gonfloni S, Superti-Furga G, Dynamic coupling between the SH2 and SH3 domains of c-Src and Hck underlies their inactivation by C-terminal tyrosine phosphorylation. Cell 2001;105(1):115-26
   PubMed Web of Science ®Google Scholar
• Schindler T, Bornmann W, Pellicena P, Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 2000;289(5486):1938-42
   PubMed Web of Science ®Google Scholar
• Hanks SK, Hunter T. Protein kinases 6. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification. Faseb J 1995;9(8):576-96
   PubMed Web of Science ®Google Scholar
• Huse M, Kuriyan J. The conformational plasticity of protein kinases. Cell 2002;109(3):275-82
   PubMed Web of Science ®Google Scholar
• Pluk H, Dorey K, Superti-Furga G. Autoinhibition of c-Abl. Cell 2002;108(2):247-59
   PubMed Web of Science ®Google Scholar
• Azam M, Latek RR, Daley GQ. Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 2003;112(6):831-43
   PubMed Web of Science ®Google Scholar
• Kirkland LO, McInnes C. Non-ATP competitive protein kinase inhibitors as anti-tumor therapeutics. Biochem Pharmacol 2009;77(10):1561-71
   PubMed Web of Science ®Google Scholar
• Bogoyevitch MA, Fairlie DP. A new paradigm for protein kinase inhibition: blocking phosphorylation without directly targeting ATP binding. Drug Discov Today 2007;12(15-16):622-33
   PubMed Web of Science ®Google Scholar
• Arkin MR, Whitty A. The road less traveled: modulating signal transduction enzymes by inhibiting their protein-protein interactions. Curr Opin Chem Biol 2009;13(3):284-90
   PubMed Web of Science ®Google Scholar
• Fojo T. Commentary: novel therapies for cancer: why dirty might be better. Oncologist 2008;13(3):277-83
   PubMed Web of Science ®Google Scholar
• Knight ZA, Lin H, Shokat KM. Targeting the cancer kinome through polypharmacology. Nat Rev 2010;10(2):130-7
   Google Scholar
• Patel RY, Doerksen RJ. Protein kinase-inhibitor database: structural variability of and inhibitor interactions with the protein kinase P-loop. J Proteome Res 2010;9(9):4433-42
   Google Scholar
• Zhang J, Adrian FJ, Jahnke W, Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature 2010;463(7280):501-6
   PubMed Web of Science ®Google Scholar
• Weisberg E, Manley PW, Cowan-Jacob SW, Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev 2007;7(5):345-56
   Google Scholar
• Shah NP, Tran C, Lee FY, Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004;305(5682):399-401
   PubMed Web of Science ®Google Scholar
• Azam M, Seeliger MA, Gray NS, Activation of tyrosine kinases by mutation of the gatekeeper threonine. Nat Struct Mol Biol 2008;15(10):1109-18
   PubMed Web of Science ®Google Scholar
• Kornev AP, Haste NM, Taylor SS, Eyck LF. Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism. Proc Natl Acad Sci USA 2006;103(47):17783-8
   PubMed Web of Science ®Google Scholar
• Simard JR, Kluter S, Grutter C, A new screening assay for allosteric inhibitors of cSrc. Nat Chem Biol 2009;5(6):394-6
   PubMed Web of Science ®Google Scholar
• Getlik M, Grutter C, Simard JR, Hybrid compound design to overcome the gatekeeper T338M mutation in cSrc. J Med Chem 2009;52(13):3915-26
   PubMed Web of Science ®Google Scholar
• Fabbro D, Manley PW, Jahnke W, Inhibitors of the Abl kinase directed at either the ATP- or myristate-binding site. Biochim Biophys Acta 2010;1804(3):454-62
   PubMed Web of Science ®Google Scholar
• Adrian FJ, Ding Q, Sim T, Allosteric inhibitors of Bcr-abl-dependent cell proliferation. Nat Chem Biol 2006;2(2):95-102
   PubMed Web of Science ®Google Scholar
• Irmer D, Funk JO, Blaukat A. EGFR kinase domain mutations – functional impact and relevance for lung cancer therapy. Oncogene 2007;26(39):5693-701
   PubMed Web of Science ®Google Scholar
• van Erp NP, Gelderblom H, Guchelaar HJ. Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev 2009;35(8):692-706
   PubMed Web of Science ®Google Scholar
• Yano S, Wang W, Li Q, Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res 2008;68(22):9479-87
   PubMed Web of Science ®Google Scholar
• Burchert A. Roots of imatinib resistance: a question of self-renewal? Drug Resist Updat 2007;10(4-5):152-61
   PubMed Web of Science ®Google Scholar
• Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev 2007;7(3):169-81
   Google Scholar
• Engelman JA, Zejnullahu K, Mitsudomi T, MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316(5827):1039-43
   PubMed Web of Science ®Google Scholar
• Rosell R, Viteri S, Molina MA, Epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in advanced nonsmall-cell lung cancer. Curr Opin Oncol 2010;22(2):112-20
   PubMed Web of Science ®Google Scholar
• Ferguson KM. Structure-based view of epidermal growth factor receptor regulation. Annu Rev Biophys 2008;37:353-73
   PubMed Web of Science ®Google Scholar
• Zhang X, Gureasko J, Shen K, An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 2006;125(6):1137-49
   PubMed Web of Science ®Google Scholar
• Yun CH, Boggon TJ, Li Y, Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell 2007;11(3):217-27
   PubMed Web of Science ®Google Scholar
• Choong NW, Dietrich S, Seiwert TY, Gefitinib response of erlotinib-refractory lung cancer involving meninges – role of EGFR mutation. Nat Clin Pract Oncol 2006;3(1):50-7; quiz 1 p following 7
   PubMedGoogle Scholar
• Iacob RE, Pene-Dumitrescu T, Zhang J, Conformational disturbance in Abl kinase upon mutation and deregulation. Proc Natl Acad Sci USA 2009;106(5):1386-91
   PubMed Web of Science ®Google Scholar
• Shah NP, Nicoll JM, Nagar B, Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002;2(2):117-25
   PubMed Web of Science ®Google Scholar
• Cowan-Jacob SW, Fendrich G, Floersheimer A, Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia. Acta Crystallogr D Biol Crystallogr 2007;63(Pt 1):80-93
   PubMedGoogle Scholar
• Cowan-Jacob SW, Guez V, Fendrich G, Imatinib (STI571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatment. Mini Rev Med Chem 2004;4(3):285-99
   PubMed Web of Science ®Google Scholar
• Carlomagno F, Guida T, Anaganti S, Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors. Oncogene 2004;23(36):6056-63
   PubMed Web of Science ®Google Scholar
• Liu J, Joha S, Idziorek T, BCR-ABL mutants spread resistance to non-mutated cells through a paracrine mechanism. Leukemia 2008;22(4):791-9
   PubMed Web of Science ®Google Scholar
• Yun CH, Mengwasser KE, Toms AV, The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci USA 2008;105(6):2070-5
   PubMed Web of Science ®Google Scholar
• Bell DW, Gore I, Okimoto RA, Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Nat Genet 2005;37(12):1315-16
   PubMed Web of Science ®Google Scholar
• Bossemeyer D. The glycine-rich sequence of protein kinases: a multifunctional element. Trends Biochem Sci 1994;19(5):201-5
   PubMed Web of Science ®Google Scholar
• Madhusudan, Akamine P, Xuong NH, Taylor SS. Crystal structure of a transition state mimic of the catalytic subunit of cAMP-dependent protein kinase. Nat Struct Biol 2002;9(4):273-7
   PubMedGoogle Scholar
• Liao JJ. Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors. J Med Chem 2007;50(3):409-24
   PubMed Web of Science ®Google Scholar
• Zhou T, Parillon L, Li F, Crystal structure of the T315I mutant of AbI kinase. Chem Biol Drug Des 2007;70(3):171-81
   PubMed Web of Science ®Google Scholar
• Young MA, Shah NP, Chao LH, Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680. Cancer Res 2006;66(2):1007-14
   PubMed Web of Science ®Google Scholar
• Avizienyte E, Ward RA, Garner AP. Comparison of the EGFR resistance mutation profiles generated by EGFR-targeted tyrosine kinase inhibitors and the impact of drug combinations. Biochem J 2008;415(2):197-206
   PubMed Web of Science ®Google Scholar
• Halilovic E, Solit DB. Therapeutic strategies for inhibiting oncogenic BRAF signaling. Curr Opin Pharmacol 2008;8(4):419-26
   PubMed Web of Science ®Google Scholar
• Wan PT, Garnett MJ, Roe SM, Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004;116(6):855-67
   PubMed Web of Science ®Google Scholar
• Linardou H, Dahabreh IJ, Bafaloukos D, Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC. Nat Rev Clin Oncol 2009;6(6):352-66
   PubMed Web of Science ®Google Scholar
• Skaggs BJ, Gorre ME, Ryvkin A, Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants. Proc Natl Acad Sci USA 2006;103(51):19466-71
   PubMed Web of Science ®Google Scholar
• Griswold IJ, MacPartlin M, Bumm T, Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib. Mol Cell Biol 2006;26(16):6082-93
   PubMed Web of Science ®Google Scholar
• Seeliger MA, Ranjitkar P, Kasap C, Equally potent inhibition of c-Src and Abl by compounds that recognize inactive kinase conformations. Cancer Res 2009;69(6):2384-92
   PubMed Web of Science ®Google Scholar
• Roumiantsev S, Shah NP, Gorre ME, Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop. Proc Natl Acad Sci USA 2002;99(16):10700-5
   PubMed Web of Science ®Google Scholar
• Vajpai N, Strauss A, Fendrich G, Solution conformations and dynamics of ABL kinase-inhibitor complexes determined by NMR substantiate the different binding modes of imatinib/nilotinib and dasatinib. J Biol Chem 2008;283(26):18292-302
   PubMed Web of Science ®Google Scholar
• Nagar B, Bornmann WG, Pellicena P, Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res 2002;62(15):4236-43
   PubMed Web of Science ®Google Scholar
• Burgess MR, Skaggs BJ, Shah NP, Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance. Proc Natl Acad Sci USA 2005;102(9):3395-400
   PubMed Web of Science ®Google Scholar
• Lee TS, Potts SJ, Kantarjian H, Molecular basis explanation for imatinib resistance of BCR-ABL due to T315I and P-loop mutations from molecular dynamics simulations. Cancer 2008;112(8):1744-53
   PubMed Web of Science ®Google Scholar
• Squire CJ, Dickson JM, Ivanovic I, Baker EN. Structure and inhibition of the human cell cycle checkpoint kinase, Wee1A kinase: an atypical tyrosine kinase with a key role in CDK1 regulation. Structure 2005;13(4):541-50
   PubMed Web of Science ®Google Scholar
• Nguyen KS, Kobayashi S, Costa DB. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin Lung Cancer 2009;10(4):281-9
   PubMed Web of Science ®Google Scholar
• Gajiwala KS, Wu JC, Christensen J, KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients. Proc Natl Acad Sci USA 2009;106(5):1542-7
   PubMed Web of Science ®Google Scholar
• Lasota J, Miettinen M. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours. Histopathology 2008;53(3):245-66
   PubMed Web of Science ®Google Scholar
• Heinrich MC, Maki RG, Corless CL, Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol 2008;26(33):5352-9
   PubMed Web of Science ®Google Scholar
• Nishida T, Kanda T, Nishitani A, Secondary mutations in the kinase domain of the KIT gene are predominant in imatinib-resistant gastrointestinal stromal tumor. Cancer Sci 2008;99(4):799-804
   PubMed Web of Science ®Google Scholar
• Roberts KG, Odell AF, Byrnes EM, Resistance to c-KIT kinase inhibitors conferred by V654A mutation. Mol Cancer Ther 2007;6(3):1159-66
   PubMed Web of Science ®Google Scholar
• Fletcher JA, Rubin BP. KIT mutations in GIST. Curr Opin Genet Dev 2007;17(1):3-7
   PubMed Web of Science ®Google Scholar
• Tang Z, Jiang S, Du R, Disruption of the EGFR E884-R958 ion pair conserved in the human kinome differentially alters signaling and inhibitor sensitivity. Oncogene 2009;28(4):518-33
   PubMed Web of Science ®Google Scholar
• Lee F, Fandi A, Voi M. Overcoming kinase resistance in chronic myeloid leukemia. Int J Biochem Cell Biol 2008;40(3):334-43
   PubMed Web of Science ®Google Scholar
• Mager DE. Quantitative structure-pharmacokinetic/pharmacodynamic relationships. Adv Drug Deliv Rev 2006;58(12-13):1326-56
   PubMed Web of Science ®Google Scholar
• Shah NP, Kim DW, Kantarjian H, Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. Haematologica 2010;95(2):232-40
   PubMed Web of Science ®Google Scholar
• Snead JL, O'Hare T, Adrian LT, Acute dasatinib exposure commits Bcr-Abl-dependent cells to apoptosis. Blood 2009;114(16):3459-63
   PubMed Web of Science ®Google Scholar
• Petak I, Schwab R, Orfi L, Integrating molecular diagnostics into anticancer drug discovery. Nat Rev Drug Discov 2010;9(7):523-35
   PubMed Web of Science ®Google Scholar
• Karaman MW, Herrgard S, Treiber DK, A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 2008;26(1):127-32
   PubMed Web of Science ®Google Scholar
• Mak DH, Schober WD, Chen W, Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells. Mol Cancer Ther 2009;8(9):2509-16
   PubMed Web of Science ®Google Scholar
• von Bubnoff N, Manley PW, Mestan J, Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107). Blood 2006;108(4):1328-33
   PubMed Web of Science ®Google Scholar
• Bradeen HA, Eide CA, O'Hare T, Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood 2006;108(7):2332-8
   PubMed Web of Science ®Google Scholar
• Ray A, Cowan-Jacob SW, Manley PW, Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study. Blood 2007;109(11):5011-15
   PubMed Web of Science ®Google Scholar
• Zhou W, Ercan D, Chen L, Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 2009;462(7276):1070-4
   PubMed Web of Science ®Google Scholar
• Weisberg E, Sattler M, Ray A, Griffin JD. Drug resistance in mutant FLT3-positive AML. Oncogene 2010;29(37):5120-34
   Google Scholar
• Redaelli S, Piazza R, Rostagno R, Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. J Clin Oncol 2009;27(3):469-71
   PubMed Web of Science ®Google Scholar
• Weisberg E, Choi HG, Ray A, Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRalpha, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants. Blood 2010;115(21):4206-16
   PubMed Web of Science ®Google Scholar
• Choi HG, Ren P, Adrian F, A type-II kinase inhibitor capable of inhibiting the T315I ‘gatekeeper’ mutant of Bcr-Abl. J Med Chem 2010;53(15):5439-48
   PubMed Web of Science ®Google Scholar
• Thomas RK, Baker AC, Debiasi RM, High-throughput oncogene mutation profiling in human cancer. Nat Genet 2007;39(3):347-51
   PubMed Web of Science ®Google Scholar
• Maecker HT, Nolan GP, Fathman CG. New technologies for autoimmune disease monitoring. Curr Opin Endocrinol Diabetes Obes 2010;17(4):322-8
   PubMed Web of Science ®Google Scholar
• Goldstein DM, Gray NS, Zarrinkar PP. High-throughput kinase profiling as a platform for drug discovery. Nat Rev Drug Discov 2008;7(5):391-7
   PubMed Web of Science ®Google Scholar
• von Bubnoff N, Barwisch S, Speicher MR, A cell-based screening strategy that predicts mutations in oncogenic tyrosine kinases: implications for clinical resistance in targeted cancer treatment. Cell Cycle 2005;4(3):400-6
   PubMed Web of Science ®Google Scholar
• von Bubnoff N, Engh RA, Aberg E, FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro. Cancer Res 2009;69(7):3032-41
   PubMed Web of Science ®Google Scholar
• Yu Z, Boggon TJ, Kobayashi S, Resistance to an irreversible epidermal growth factor receptor (EGFR) inhibitor in EGFR-mutant lung cancer reveals novel treatment strategies. Cancer Res 2007;67(21):10417-27
   PubMed Web of Science ®Google Scholar
• Faley SL, Copland M, Wlodkowic D, Microfluidic single cell arrays to interrogate signalling dynamics of individual, patient-derived hematopoietic stem cells. Lab Chip 2009;9(18):2659-64
   PubMed Web of Science ®Google Scholar
• Schadt EE, Linderman MD, Sorenson J, Computational solutions to large-scale data management and analysis. Nat Rev Genet 2010;11(9):647-57
   PubMed Web of Science ®Google Scholar
• Marsden BD, Knapp S. Doing more than just the structure-structural genomics in kinase drug discovery. Curr Opin Chem Biol 2008;12(1):40-5
   PubMed Web of Science ®Google Scholar
• Chu SH, Small D. Mechanisms of resistance to FLT3 inhibitors. Drug Resist Updat 2009;12(1-2):8-16
   PubMed Web of Science ®Google Scholar
• Lierman E, Michaux L, Beullens E, FIP1L1-PDGFRalpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRalpha T674I eosinophilic leukemia with single agent sorafenib. Leukemia 2009;23(5):845-51
   PubMed Web of Science ®Google Scholar
• Bean J, Riely GJ, Balak M, Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma. Clin Cancer Res 2008;14(22):7519-25
   PubMed Web of Science ®Google Scholar
• Foster DA, Toschi A. Targeting mTOR with rapamycin: one dose does not fit all. Cell Cycle 2009;8(7):1026-9
   PubMed Web of Science ®Google Scholar
• Klebl BM, Muller G. Second-generation kinase inhibitors. Expert Opin Ther Targets 2005;9(5):975-93
   PubMed Web of Science ®Google Scholar
• Danis RP, Sheetz MJ. Ruboxistaurin: PKC-beta inhibition for complications of diabetes. Expert Opin Pharmacother 2009;10(17):2913-25
   PubMed Web of Science ®Google Scholar
• Lapenna S, Giordano A. Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov 2009;8(7):547-66
   PubMed Web of Science ®Google Scholar
• Strebhardt K. Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy. Nat Rev Drug Discov 2010;9(8):643-60
   PubMed Web of Science ®Google Scholar
• Xue Q, Hopkins B, Perruzzi C, Palomid 529, a novel small-molecule drug, is a TORC1/TORC2 inhibitor that reduces tumor growth, tumor angiogenesis, and vascular permeability. Cancer Res 2008;68(22):9551-7
   PubMed Web of Science ®Google Scholar
• NCI. NCI Clinical Trial Search Webpage. [Webpage] 2010. Available from: http://www.cancer.gov/clinicaltrials [Cited]
   Google Scholar
• Gonfloni S, Weijland A, Kretzschmar J, Superti-Furga G. Crosstalk between the catalytic and regulatory domains allows bidirectional regulation of Src. Nat Struct Biol 2000;7(4):281-6
   PubMedGoogle Scholar
• Green H, Skoglund K, Rommel F, CYP3A activity influences imatinib response in patients with chronic myeloid leukemia: a pilot study on in vivo CYP3A activity. Eur J Clin Pharmacol 2010;66(4):383-6
   PubMed Web of Science ®Google Scholar
• Schindler T, Sicheri F, Pico A, Crystal structure of Hck in complex with a Src family-selective tyrosine kinase inhibitor. Mol Cell 1999;3(5):639-48
   PubMed Web of Science ®Google Scholar
• Cowan-Jacob SW, Fendrich G, Manley PW, The crystal structure of a c-Src complex in an active conformation suggests possible steps in c-Src activation. Structure 2005;13(6):861-71
   PubMed Web of Science ®Google Scholar
• Martin MW, Newcomb J, Nunes JJ, Discovery of novel 2,3-diarylfuro[2,3-b]pyridin-4-amines as potent and selective inhibitors of Lck: synthesis, SAR, and pharmacokinetic properties. Bioorg Med Chem Lett 2007;17(8):2299-304
   PubMed Web of Science ®Google Scholar